RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
Summary
H7925 would create a limited exemption from Rhode Island’s Uniform Controlled Substances Act for psilocybin. Under the bill, the controlled-substances chapter would not apply to less than one ounce of psilocybin when it is possessed by one person, shared by one person with another, or securely cultivated in a person’s residence for personal use. In effect, the bill would decriminalize a narrow amount of home-grown or personally possessed psilocybin under state law, while leaving larger amounts and other conduct outside the exemption.
The bill also sets up a future regulatory framework if federal conditions change. If the FDA reschedules psilocybin, the Rhode Island Department of Health would be required to adopt rules governing cultivation, distribution, and medical prescription. Separately, if the FDA expands its access program, patients with serious or life-threatening mental or behavioral health disorders who lack effective treatment options would be able to access psilocybin at Rhode Island locations approved by the Department of Health. The act would take effect July 1, 2026, and would sunset July 1, 2028, with reporting requirements before sunset from the attorney general and the health department on enforcement activity and federal scheduling/access developments.
Impact
The bill would amend Chapter 21-28 of the General Laws, Rhode Island’s Uniform Controlled Substances Act, by carving out a specific exemption for limited psilocybin possession and home cultivation. It would reduce the reach of state controlled-substance enforcement for small amounts of psilocybin and create a pathway for state regulation of psilocybin cultivation, distribution, and medical use if federal law or FDA programs change. The measure would also require state reporting on psilocybin enforcement and federal developments before the bill expires.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the overall posture appears exploratory and reform-oriented rather than settled or bipartisan. The bill’s structure suggests support for limited personal use and potential therapeutic access, but only within narrow limits and contingent on federal action. The sunset date and reporting requirements indicate an intent to study outcomes before making any permanent change.
Contention
The main points of contention are likely to be the decriminalization of psilocybin possession and home cultivation, and the prospect of medical access for mental and behavioral health treatment. Supporters would likely emphasize personal autonomy, harm reduction, and possible therapeutic benefits, while opponents may raise concerns about public safety, misuse, regulatory readiness, and the fact that psilocybin remains federally controlled. The bill’s reliance on FDA rescheduling and program expansion also makes its practical implementation uncertain and may be a source of debate.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.
Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.
Prohibits the manufacture, sale, and distribution of foods containing certain artificial food dyes within school systems in the State of Rhode Island commencing January 1, 2027.
A bill for an act relating to the production of psilocybin and the administration of psilocybin to persons with post-traumatic stress disorder, and providing penalties.(See HF 978.)
(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.